Filed: 5/15/2024ACC: 0000905148-24-001442
📋 What this filing means
VENBIO PARTNERS LLC filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $281.88M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$281.88M
Total AUM (reported)
21.57M
Total Shares
Allocation by class
COM$281.88M100.0%
Portfolio Concentration
Top 3$242.05M85.9%
4–10$39.84M14.1%
Top 3 weight
85.9%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 21.57M
Sole
Full voting authority
21.57M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole5
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings5
Rows:
ALX ONCOLOGY HLDGS INC
SOLEShares9.70M
TypeSH
Market value$108.15M
38.37%
Sole
9.70M
Shared
0.00
None
0.00
PHARVARIS N V
SOLEShares4.29M
TypeSH
Market value$99.13M
35.17%
Sole
4.29M
Shared
0.00
None
0.00
HARMONY BIOSCIENCES HLDGS IN
SOLEShares1.04M
TypeSH
Market value$34.77M
12.33%
Sole
1.04M
Shared
0.00
None
0.00
ACELYRIN INC
SOLEShares3.85M
TypeSH
Market value$26.00M
9.23%
Sole
3.85M
Shared
0.00
None
0.00
ELEVATION ONCOLOGY INC
SOLEShares2.70M
TypeSH
Market value$13.83M
4.91%
Sole
2.70M
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
ALX ONCOLOGY HLDGS INCSOLE | COM | 9.70M | SH | $108.15M 38.37% | 9.70M | 0.00 | 0.00 |
PHARVARIS N VSOLE | COM | 4.29M | SH | $99.13M 35.17% | 4.29M | 0.00 | 0.00 |
HARMONY BIOSCIENCES HLDGS INSOLE | COM | 1.04M | SH | $34.77M 12.33% | 1.04M | 0.00 | 0.00 |
ACELYRIN INCSOLE | COM | 3.85M | SH | $26.00M 9.23% | 3.85M | 0.00 | 0.00 |
ELEVATION ONCOLOGY INCSOLE | COM | 2.70M | SH | $13.83M 4.91% | 2.70M | 0.00 | 0.00 |